Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PROPHYLACTIC OR THERAPEUTIC AGENT FOR PROSTATE CANCER
Document Type and Number:
WIPO Patent Application WO/2019/216360
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a prophylactic or therapeutic agent which is for prostate cancer and which can be produced simply and inexpensively, and contains, as an active ingredient, a low molecular weight compound exhibiting antitumor effects even on intractable castration-resistant prostate cancers (particularly, castration-resistant prostate cancer having resistance to cabazitaxel, which is the most intractable prostate cancer). The prophylactic or therapeutic agent for prostate cancer (preferably, castration-resistant prostate cancer having resistance to cabazitaxel) contains cloperastine or a pharmaceutically acceptable salt thereof.

Inventors:
KOSAKA TAKEO (JP)
HONGO HIROSHI (JP)
OYA MOTOTSUGU (JP)
Application Number:
JP2019/018465
Publication Date:
November 14, 2019
Filing Date:
May 09, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV KEIO (JP)
International Classes:
A61K31/4453; A61P13/08; A61P35/00; A61P35/04
Domestic Patent References:
WO2012154944A22012-11-15
Foreign References:
JP2013249298A2013-12-12
JPS565511B11981-02-05
Other References:
JI, N. ET AL.: "Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 2015, pages 308475, XP055410062
BABCOCK, J. J. ET AL.: "Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors", PLOS ONE, vol. 8, no. 7, 2013, pages e69513, XP055653771
KOSAKA ET AL., J UROL, vol. 185, no. 6, June 2011 (2011-06-01), pages 2376 - 81
Attorney, Agent or Firm:
HIROTA, Masanori (JP)
Download PDF: